Graphene as basis of biological sensors for determining markers of neurodegenerative dementia

Objective. To develop technique immobilizing antibodies graphene surface of proteins that play a significant role in pathogenesis Alzheimer's disease.
Materials and methods. Graphene films were obtained sublimation surface of SiC substrates. Presence graphene monolayer was confirmed spectroscopy spectra. Graphene surface quality was evaluated cyclic voltammetry. Functionalization by amino groups was carried out method based on sorption pyrene derivatives from a solution and phenylnitrogroups electrochemical method. Graphene was kept in solutions monoclonal antibodies to human beta-amyloid peptide 1–42. Preparations were also kept in solution secondary antibodies labeled with FITZ. Results were evaluated fluorescence microscopy. Additionally, samples were kept in solution antibody with peroxidase label, which was detected chemiluminescence.
Results. For attachment specific antibodies surface of graphene, quality its surface is great importance. Optimal working concentration of antibodies of human beta-amyloid 1–42 in solution for subsequent manufacture biological sensors is 15 micrograms per 1 ml. Covalent crosslinking antibodies with glutaraldehyde with amino groups on graphene gives a slight gain in the level fluorescence compared with noncovalent sorption on graphene with nitro groups. Functionalization phenylnitrogroups is optimal for further work related to the identification specific antigens.
Conclusions. The technique of immobilization on the graphene surface of specific antibodies to beta-amyloid in concentrations detected by fluorescence microscopy and chemiluminescence is investigated. Amount antibodies sufficient to create a biosensor is immobilized on graphene. It was found that functionalization of phenylnitrogroups allows creating optimal conditions for the attachment of antibodies to the graphene surface, as well as washing resulting antibody-antigenic complexes for further reuse of graphene biosensors.

1. Scheltens P., Blennow K., Breteler M. M., et al. Alzheimer's disease. Lancet. 2016. Vol. 388, No. 10043. P. 505–517. https://doi.org/10.1016/s0140–6736(15)01124–1

2. GBD 2016 Dementia Collaborators. Global, regional, and national burden of Alzheimer's disease and other dementias, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019. Vol. 18, No. 1. P. 88–106. https://doi.org/10.1016/s1474–4422(18)30403–4

3. Niu H., Álvarez-Álvarez I., Guillén-Grima F., Aguinaga-Ontoso I. Prevalence and incidence of Alzheimer's disease in Europe: A meta-analysis. Prevalencia e incidencia de la enfermedad de Alzheimer en Europa: Metaanálisis. Neurologia. 2017. Vol. 32, No. 8. P. 523–532. https://doi.org/10.1016/j.nrl.2016.02.016

4. United Nations Department of Economic and Social Affairs, Population Division World Population Ageing 2020 Highlights: Living Arrangements of Older Persons. [(accessed on 4 April 2021)]. 2020 (ST/ESA/SER.A/451).

5. US Burden of Disease Collaborators, Mokdad A. H., Ballestros K., et al. The State of US Health, 1990–2016: Burden of Diseases, Injuries, and Risk Factors Among US States. JAMA. 2018. Vol. 319, No. 14. P. 1444–1472. https://doi.org/10.1001/jama.2018.0158

6. Salloway S., Sperling R., Fox N. C., et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N. Engl. J. Med. 2014. Vol. 370, No. 4. P. 322–333. https://doi.org/10.1056/nejmoa1304839

7. Dubois B., Feldman H. H., Jacova C., et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG‑2 criteria. Lancet Neurol. 2014. Vol. 13, No. 6. P. 614–629. https://doi.org/10.1016/S 1474–4422(14)70090–0

8. Jack C. R. Jr, Bennett D. A., Blennow K., et al. NIAAA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018. Vol. 14, No. 4. P. 535–562. https://doi.org/10.1016/j.jalz.2018.02.018

9. Hampel H., Lista S., Khachaturian Z. S. Development of biomarkers to chart all Alzheimer's disease stages: The royal road to cutting the therapeutic Gordian Knot. Alzheimers Dement. 2012. Vol. 8, No. 4. P. 312–336. https://doi.org/10.1016/j.jalz.2012.05.2116

10. Blennow K., Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol. 2003. Vol. 2, No. 10. P. 605–613. https://doi.org/10.1016/s1474–4422(03)00530–1

11. Seppälä T. T., Nerg O., Koivisto A. M., et al. CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings. Neurology. 2012. Vol. 78, No. 20. P. 1568–1575. https://doi.org/10.1212/wnl.0b013e3182563bd0

12. Portelius E., Hansson S. F., Tran A. J., et al. Characterization of tau in cerebrospinal fluid using mass spectrometry. J. Proteome Res. 2008. Vol. 7, No. 5. P. 2114–2120. https://doi.org/10.1021/pr7008669

13. Blennow K., Dubois B., Fagan A. M., et al. Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease. Alzheimers Dement. 2015. Vol. 11, No. 1. P. 58–69. https://doi.org/10.1016/j.jalz.2014.02.004

14. Suárez-Calvet M., Karikari T. K., Ashton N. J., et al. Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer's continuum when only subtle changes in Aβ pathology are detected. EMBO Mol Med. 2020. Vol. 12, No. 12. P. 12921. https://doi.org/10.15252/emmm.202012921

15. Khalil M., Teunissen C. E., Otto M., et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol. 2018. Vol. 14 No. 10. P. 577–589. https://doi.org/10.1038/s41582–018–0058-z

16. Preische O., Schultz S. A., Apel A., et al. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease. Nat Med. 2019. Vol. 25, No. 2. P. 277–283. https://doi.org/10.1038/s41591–018–0304–3

17. Mattsson N., Cullen N. C., Andreasson U., et al. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients with Alzheimer Disease. JAMA Neurol. 2019. Vol. 76, No. 7. P. 791–799. https://doi.org/10.1001/jamaneurol.2019.0765

18. Quiroz Y. T., Zetterberg H., Reiman E. M., et al. Plasma neurofilament light chain in the presenilin 1 E 280A autosomal dominant Alzheimer's disease kindred: A cross-sectional and longitudinal cohort study. Lancet Neurol. 2020. Vol. 19, No. 6. P. 513–521. https://doi.org/10.1016/s1474–4422(20)30137-x

19. Duits F. H., Martinez-Lage P., Paquet C., et al. Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lumbar puncture feasibility study. Alzheimers Dement. 2016. Vol. 12, No. 2. P. 154–163. https://doi.org/10.1016/j.jalz.2015.08.003

20. Palmqvist S., Janelidze S., Stomrud E., et al. Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease-Related β-Amyloid Status. JAMA Neurol. 2019. Vol. 76, No. 9. P. 1060–1069. https://doi.org/10.1001/jamaneurol.2019.1632

21. Schindler S. E., Bollinger J. G., Ovod V., et al. High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis. Neurology. 2019. Vol. 93, No. 17. P. 1647–e1659. https://doi.org/10.1212/wnl.0000000000008081

22. Demeritte T., Nellore B. P., Kanchanapally R., et al. Hybrid Graphene Oxide Based Plasmonic-Magnetic Multifunctional Nanoplatform for Selective Separation and Label-Free Identification of Alzheimer's Disease Biomarkers. ACS Appl Mater Interfaces. 2015. Vol. 7, No. 24. P. 13693–13700. https://doi.org/10.1021/acsami.5b03619

23. Sun L., Zhong Y., Gui J., et al. A hydrogel biosensor for high selective and sensitive detection of amyloid-beta oligomers. Int. J. Nanomedicine. 2018. Vol. 13. P. 843–856. https://doi.org/10.2147/ijn.s152163

24. Lebedev A. A., Lebedev S. P., Novikov S. N., et al. Supersensitive graphenebased gas sensor. Technical Physics. 2016; 86 (3): 135 (In Russ). https://doi.org/10.1134/s1063784216030130

25. Davydov V. Yu., Usachyov D. Yu., Lebedev S. P., et al. Study of the crystal and electronic structure of graphene films grown on 6h-SiC (0001). Semiconductors. 2017; 51 (8): 1116–1124 (In Russ). https://doi.org/10.21883/ftp.2017.08.44800.8559

26. Torrente-Rodríguez R.M., Lukas H., Tu J., et al. SARS-CoV‑2 RapidPlex: A Graphene-Based Multiplexed Telemedicine Platform for Rapid and Low-Cost COVID‑19 Diagnosis and Monitoring. Matter. 2020. Vol. 3, No. 6. P. 1981–1998. https://doi.org/10.1016/j.matt.2020.09.027

27. Plekhanov A. Yu. Immunoreplica from the gel surface: Rapid and sensitive blot plus intact gel. Analytical Biochemistry. 1996. Vol. 239, No. 1. P. 110–111. https://doi.org/10.1006/abio.1996.0298

28. Usikov A. S., Lebedev S. P., Roenkov A. D., et al. Investigation of graphene's sensing ability for applications as biosensors. Technical Physics Letters. 2020; 46 (10): 3–6 (In Russ). DOI: 10.21883/pjtf.2020.10.49421.18250

29. Plekhanov A. Yu., Puzyk M. V., Usikov A. S., et al. Chemiluminescence of a functionalized graphene surface. Optics and Spectroscopy. 2022; 130 (9): 1417–1422 (In Russ). https://doi.org/10.21883/os.2022.09.53305.3628–22